# Immix Biopharma Inc. (IMMX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $7.71, market value $639 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Immix Biopharma Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.4×**. The shares trade at 2.4× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -6.1%** (5-yr avg -15.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -31.4%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -17.1%**. Earnings per share fell 17.1%.

## Financial health
- **Current ratio: 10.01** (quick 10.01). Current assets cover the next year's liabilities 10.01 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Immix Biopharma Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (8 analysts). 8 analysts cover Immix Biopharma Inc.; the consensus is strong_buy, with an average price target of $24.05 (+212% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 91.1%** (YTD 38.8%, 3-mo -13.8%). The shares are up 91.1% over twelve months including dividends.
- **From 52-week high: -48.9%** (170.4% above the low). Trading 49% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 27**. An RSI of 27 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 1.59** (volatility 84%). Beta of 1.59 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IMMX · Page: https://foliofundamentals.com/stocks/immx

Not investment advice.